The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | International ABNL-MARRO trial for MDS/MPN overlap syndromes
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the ABNL-MARRO trial (NCT04061421), a basket study of novel therapy for untreated myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) and relapsed/refractory MDS/MPN overlap syndromes, such as chronic myelomonocytic leukemia (CMML). Beyond the primary objectives of evaluating the safety and efficacy of novel treatment combinations, this international co-operative trial will provide a novel framework for future trials in MDS/MPN and explore clinicopathological biomarkers. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
